Description

Synergistic GH Releasing Compositions: Ipamorelin + CJC

The combination of Ipamorelin + CJC represents a prominent research stack in cellular metabolism and growth hormone secretagogue (GHS) studies. By targeting two distinct receptor pathways on anterior pituitary somatotrophs, this co-formulation produces a synergistic release of endogenous growth hormone (GH) without causing significant elevations in secondary hormones such as cortisol or prolactin. Sourcing analytical-grade research materials ensures high reproducibility across in vitro receptor binding assays, cellular signaling experiments, and endocrine pathway studies.

Technical & Product Specifications

• Size: 10mg (Ipamorelin 5mg, CJC-1295 no DAC 5mg) |

• Overall Purity: >99% Purity

Ipamorelin Specifications:

• CAS No.: 170851-70-4

• Molecular Weight: 711.85 g/mol

• Half-Life: ~2 hours

• Storage: Store at -20℃ (up to 3 years)

CJC-1295 no DAC Specifications:

• CAS No.: 863288-34-0

• Molecular Weight: 3,367.9 g/mol

• Half-Life: ~0.5 hours

• Storage: Store at -20℃ (up to 3 years)

Complementary Receptor Agonism

Growth hormone secretion is naturally regulated by two separate signals: Growth Hormone-Releasing Hormone (GHRH) and Ghrelin. Evaluating cjc ipamorelin co-administration allows researchers to observe dual-pathway activation in real time:

• GHRH Pathway Activation: CJC-1295 (Modified GRF 1-29) acts as a GHRH receptor agonist, stimulating adenylate cyclase and increasing intracellular cyclic AMP (cAMP) levels to drive GH synthesis and basal release.

• Ghrelin Receptor (GHS-R1a) Agonism: As a selective ipamorelin peptide, Ipamorelin binds specifically to the ghrelin receptor, triggering intracellular calcium influx to stimulate acute GH release.

When deployed simultaneously, the stack amplifies natural GH pulse amplitude far beyond the additive effects of either single compound, offering superior theoretical yield in secretion assays.

Experimental Considerations & Assay Design

In preclinical research models, establishing a precise ipamorelin dosage and concentration profile requires careful consideration of individual peptide half-lives and cellular receptor desensitization kinetics. The use of cjc-1295 + ipamorelin without Drug Affinity Complex (No DAC) provides a short half-life (~0.5 hours for CJC-1295 and ~2 hours for Ipamorelin), enabling tight experimental control over pulsatile GH spikes without causing long-term receptor downregulation. Analytical testing relies on pure, lyophilized formats stored at low temperatures (-20℃) to prevent premature hydrolysis or degradation.

Analytical Reagents by Receptor Chemicals

Receptor Chemicals provides high-purity research compounds engineered to meet rigorous laboratory standards. Each peptide batch undergoes comprehensive mass spectrometry and HPLC validation to guarantee structural integrity, precise stoichiometric balance, and reliable performance in advanced bioenergetic and endocrine research.